| scholarly article | Q13442814 |
| P2093 | author name string | L. D. Smith | |
| J. K. Penry | |||
| J. J. Cereghino | |||
| J. T. Brock | |||
| B. G. White | |||
| J. C. Van Meter | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | carbamazepin | Q410412 |
| pharmacology | Q128406 | ||
| P304 | page(s) | 733-741 | |
| P577 | publication date | 1975-12-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | The efficacy of carbamazepine combinations in epilepsy | |
| P478 | volume | 18 |
| Q40142216 | Anticonvulsant drugs. An update |
| Q37809292 | Antiepileptic drug therapy the story so far |
| Q37901704 | Antiepileptic drug therapy: does mechanism of action matter? |
| Q40780187 | Antiepileptic drugs. A review of clinically significant drug interactions. |
| Q40796225 | Antiepileptic medication interactions. |
| Q40265358 | Antiepileptic therapeutic drug monitoring. |
| Q36706570 | Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism |
| Q40877361 | Clinical Pharmacokinetics of Carbamazepine |
| Q37920931 | Clinically relevant anti-epileptic drug interactions |
| Q34403438 | Clinically significant pharmacokinetic drug interactions with carbamazepine. An update |
| Q36622991 | Combination therapy in epilepsy: when and what to use. |
| Q35063200 | Current limitations of antiepileptic drug therapy: a conference review. |
| Q37696491 | Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy |
| Q40626178 | Newer antiepileptic drugs. Towards an improved risk-benefit ratio |
| Q30474822 | PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLD |
| Q89714642 | Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice |
| Q37909318 | Pharmacokinetic drug interactions with phenytoin (Part II). |
| Q39675120 | Pharmacotherapeutic and Non-Pharmacological Options for Refractory and Difficult-to-Treat Seizures |
| Q24201696 | Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures |
| Q24248718 | Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures |
| Q34558578 | Place of polytherapy in the early treatment of epilepsy |
| Q33668845 | Population-based investigations of drug relative clearance using nonlinear mixed-effect modelling from information generated during the routine clinical care of patients |
| Q33664046 | Rational Polytherapy with Antiepileptic Drugs |
| Q37585499 | Rational polytherapy |
| Q40160330 | Reassessment of the concept of a therapeutic range of anticonvulsant plasma levels |
| Q34174078 | Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone |
| Q36999697 | Reversal by phenytoin of carbamazepine-induced water intoxication: a pharmacokinetic interaction |
| Q71058430 | Role of carbamazepine in reducing polypharmacy in epilepsy |
| Q47869836 | Selecting Rational Drug Combinations in Epilepsy |
| Q34082054 | Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed |
| Q34314537 | The star systems: overview and use in determining antiepileptic drug choice |
| Q38099503 | When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy |
Search more.